[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100294754":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":22,"centralContacts":26,"locations":31,"responsibleParty":52,"collaborators":54,"id":58,"slug":59,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":10,"eligibilityCriteria":64,"healthyVolunteers":60,"sex":65,"minAge":66,"maxAge":67,"enrollmentInfo":68,"targetDuration":71,"studyType":72,"phases":10,"briefSummary":73,"conditions":74,"keywords":77,"overallStatus":33,"whyStopped":10,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":91},{"fullName":5,"class":6},"Samsung Medical Center","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Lymphoma",null,"Patients are diagnosed with aggressive lymphoma including Hodgkin and non-Hodgkin lymphoma. All patients should receive systemic chemotherapy. Newly diagnosed or relapsed\u002Frefractory patients can be enrolled.",[13],"Drug: Chemotherapy",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Chemotherapy","Systemic chemotherapy with curative intent",[9],[21],"Treatment",[23],{"name":24,"affiliation":5,"role":25},"Seok Jin Kim, MD, PhD","PRINCIPAL_INVESTIGATOR",[27],{"name":24,"role":28,"phone":29,"phoneExt":10,"email":30},"CONTACT","+82234101766","kstwoh@skku.edu",[32],{"facility":5,"status":33,"city":34,"state":10,"zip":35,"country":36,"countryCode":10,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"RECRUITING","Seoul","135-710","South Korea",{"type":38,"coordinates":39},"Point",[40,41],126.9784,37.566,{"lat":41,"lon":40},[44,46,47,50],{"name":24,"role":28,"phone":45,"phoneExt":10,"email":30},"82-2-3410-1766",{"name":24,"role":25,"phone":10,"phoneExt":10,"email":10},{"name":48,"role":49,"phone":10,"phoneExt":10,"email":10},"Won Seog Kim, MD, PhD","SUB_INVESTIGATOR",{"name":51,"role":49,"phone":10,"phoneExt":10,"email":10},"Sivia Park, MD, PhD",{"type":53,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[55],{"name":56,"class":57},"Samsung Genomic Institute","UNKNOWN","100294754","prospective-cohort-study-for-lymphoma-samsung-lymphoma-cohort-study-iii-100294754",false,"NCT03117036","Prospective Cohort Study for Lymphoma: Samsung Lymphoma Cohort Study III","A Prospective Study for Patients With Lymphoid Malignancy at the Samsung Medical Center","Inclusion Criteria:\n\n1. Pathologically diagnosed Hodgkin and non-Hodgkin lymphomas\n2. 20 years\n3. Patients requiring systemic chemotherapy with curative intent\n4. Written informed consent\n\nExclusion Criteria:\n\n1. Myeloid malignancy\n2. Multiple myeloma\n3. Patients do not require systemic chemotherapy with curative intent","ALL","20 Years","90 Years",{"count":69,"type":70},600,"ESTIMATED","3 Years","OBSERVATIONAL","This prospective study enrolls patients who are diagnosed with aggressive lymphoma including Hodgkin and non-Hodgkin lymphomas. Enrolled patients will be treated according to our institution' treatment policy in clinical practice. The disease status including response to therapy and survival status will be regularly updated during the study period. Patients' serum and cell-free DNA will be collected and analyzed.",[75,76],"Lymphoma, Non-Hodgkin","Lymphoma, Hodgkin",[78,79,80,81],"lymphoma","cohort","serum","cell-free DNA","2025-05-18",{"date":84,"type":85},"2025-05-21","ACTUAL",{"date":87,"type":85},"2017-03-01",{"date":89,"type":70},"2026-12-28",{"name":5,"class":6},1]